Effects of viral respiratory infections on lung development and childhood asthma - 18/08/11
Madison, WisThis activity is available for CME credit. See page 30A for important information.
Abstract |
Viral infections are closely linked to wheezing in infancy, and those children with recurrent virus-induced wheezing episodes are at great risk for chronic childhood asthma. Infancy is a time of increased susceptibility to viral infections, and this stage is also characterized by pulmonary alveolar multiplication and extensive remodeling of the airways to accommodate growth. This coincidence, together with the observation that children with asthma can have structural lung changes and functional deficits at an early age, suggests that viral infections could adversely affect lung development. Inflammatory mediators induced by viral infection are known to have effects on the remodeling process, suggesting a plausible mechanism to support this theory. Furthermore, animal models of viral infection during lung growth and development suggest that developmental factors are important in determining the consequences of infection on long-term lung function. Greater understanding of the effects of viral infections on lung development and growth in early childhood might lead to the discovery of additional strategies for the prevention of recurrent wheezing and chronic asthma.
El texto completo de este artículo está disponible en PDF.Key words : Viral infection, respiratory syncytial virus, rhinovirus, children, lung development, cytokines, asthma
Abbreviations used : BN, EGF, LRI, OR, PIV, RSV
Esquema
Series editors: William T. Shearer, MD, PhD, Lanny J. Rosenwasser, MD, and Bruce S. Bochner, MD Supported by National Institutes of Health grants R01HL61879-01, P01HL70831-01, and N01-AI-25496. Potential conflict of interest: Dr Lemanske has consultant arrangements with Aventis, AstraZeneca, and Novartis; receives grants and research support from the National Heart, Lung, and Blood Institute; and serves on speaker's bureaus for GlaxoSmithKline, Merck, Aventis, and AstraZeneca. Drs Gern, Rosenthal, and Sorkness have declared no conflict of interest. |
Vol 115 - N° 4
P. 668-674 - avril 2005 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?